ESMO · Madrid · 2026-10-23 – 2026-10-27
ESMO Congress 2026
91 di 91 studi Late-Breaking Abstracts con risultatoIl congresso è concluso: ogni studio mostra qui il risultato non appena è nel registro.
ven 23 ott
Proffered paper 1: Breast cancer, early and advanced stage
13:30–15:00 (Europe/Madrid) · Alicante Auditorium - Hall 6- 13:30TALENTOnco · Mammella · HR+/HER2-low early breast cancer, neoadjuvantIn patients with untreated HR+/HER2-low early breast cancer, neoadjuvant T-DXd alone, with anastrozole or followed by docetaxel plus cyclophosphamide was associated with low rates of pathologic complete response.Leggi →
- 13:40HORIZON-Breast06Onco · Mammella · HER2-low advanced breast cancerIn patients with HER2-low advanced breast cancer and no more than one prior line of chemotherapy for metastatic disease, trastuzumab rezetecan improved progression-free survival by blinded independent central review compared with physician's choice of chemotherapy.Leggi →
- 13:50APEX-Breast01Onco · Mammella · HER2-low metastatic breast cancerIn patients with HR-positive, HER2-low recurrent or metastatic breast cancer, TQB2102 improved progression-free survival by blinded independent review compared with physician's choice chemotherapy.Leggi →
- 14:15NSABP B-42Onco · Mammella · HR-positive early breast cancer, extended adjuvant endocrine therapyIn postmenopausal women with hormone-receptor positive breast cancer who were disease-free after 5 years of aromatase inhibitor-based adjuvant therapy, 5 further years of letrozole modestly improved 15-year disease-free survival, but not overall survival, compared with placebo.Leggi →
- 14:25NATALEEOnco · Mammella · HR+/HER2− early breast cancer, adjuvantIn patients with high-risk stage II/III HR+/HER2− early breast cancer, adjuvant ribociclib plus a nonsteroidal aromatase inhibitor improved overall survival and invasive disease-free survival at 6 years compared with a nonsteroidal aromatase inhibitor alone.Leggi →
- 14:35PANKU-Breast01Onco · Mammella · HR+/HER2- metastatic, pretreatedIn previously treated unresectable locally advanced or metastatic HR+/HER2- breast cancer, izalontamab brengitecan improved progression-free survival by blinded independent central review compared with chemotherapy of physician's choice.Leggi →
Proffered paper 1: Gastrointestinal tumour, upper digestive
13:30–15:00 (Europe/Madrid) · Almeria Auditorium - Hall 9- 13:30G-HOPE-001Onco · GI · gastric/GEJIn previously treated CLDN18.2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma, arcotatug tavatecan improved progression-free survival compared with treatment of physician's choice.Leggi →
- 13:40SANOOnco · GI · oesophagealIn patients with oesophageal cancer and a complete clinical response after neoadjuvant chemoradiotherapy, active surveillance showed no statistically significant difference in five-year overall survival compared with standard surgery.Leggi →
- 14:22RASolute 302Onco · GI · Pancreatic cancerIn previously treated metastatic pancreatic adenocarcinoma, daraxonrasib showed a directionally consistent overall survival benefit across tumour RAS mutation subgroups compared with standard chemotherapy.Leggi →
- 14:32AMPLIFY-7POnco · GI · pancreaticIn patients with resected KRAS-mutated pancreatic ductal adenocarcinoma, the mKRAS-specific vaccine camupepimut did not improve investigator-assessed disease-free survival compared with observation.Leggi →
Rapid oral: Genitourinary tumours, prostate, penile and testis
13:30–15:00 (Europe/Madrid) · Bilbao Auditorium - Hall 3- 14:34CAPItello-281Onco · UG · prostateIn patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, capivasertib plus abiraterone did not significantly improve overall survival compared with placebo plus abiraterone at this updated analysis, although the hazard ratio favoured capivasertib.Leggi →
Proffered paper: Melanoma and other skin tumours
16:15–17:45 (Europe/Madrid) · Barcelona Auditorium - Hall 9- 16:25HBI-8000-303Onco · Melanoma · Advanced melanoma, anti-PD(L)-1 naiveIn patients with advanced melanoma not previously treated with anti-PD(L)-1 therapy, HBI-8000 plus nivolumab improved progression-free survival compared with placebo plus nivolumab.Leggi →
- 17:10MIZAR-003Onco · Melanoma · cellular therapyIn patients with anti-PD-1-resistant advanced melanoma, GC101 TIL with sintilimab improved independently assessed progression-free survival compared with investigator-choice chemotherapy.Leggi →
Rapid oral 1: Gastrointestinal tumour, upper digestive
16:15–17:45 (Europe/Madrid) · Almeria Auditorium - Hall 9- 16:15HERIZON-GEA-01Onco · GI · gastroesophagealIn patients with untreated HER2-positive advanced or metastatic gastroesophageal adenocarcinoma, zanidatamab plus chemotherapy improved overall survival compared with trastuzumab plus chemotherapy.Leggi →
- 16:20KC-WISEOnco · GI · gastric and gastroesophageal junctionIn patients with HER2-positive GC/GEJC whose previous therapy containing trastuzumab had failed, anbenitamab plus chemotherapy significantly improved overall survival compared with standard of care.Leggi →
- 16:52LOMACOnco · GI · gastricIn patients with stage II-IIIB gastric cancer after curative D2 resection, four months of adjuvant XELOX was non-inferior for 3-year disease-free survival compared with six months of adjuvant XELOX.Leggi →
Rapid oral 1: Gynaecological cancers
16:15–17:45 (Europe/Madrid) · Burgos Auditorium - Hall 3- 16:37DOVACCOnco · Gin · ovarianIn patients with BRCA-wildtype recurrent ovarian cancer, adding UV1 vaccination to olaparib plus durvalumab maintenance did not significantly improve progression-free survival compared with olaparib alone.Leggi →
Rapid oral: Breast cancer, early stage
16:15–17:45 (Europe/Madrid) · Alicante Auditorium - Hall 6- 17:14AIUROnco · Mammella · supportive care: chemotherapy-induced peripheral neuropathyIn patients with stage II-III breast cancer receiving paclitaxel, compression with normal-sized surgical gloves did not reduce patient-reported worsening of peripheral neuropathy compared with no intervention.Leggi →
sab 24 ott
Proffered paper 2: Breast cancer, early and advanced stage
08:30–10:00 (Europe/Madrid) · Alicante Auditorium - Hall 6- 08:30KEYNOTE-B49Onco · Mammella · HR+/HER2− advanced breast cancerIn patients with PD-L1 CPS ≥1 HR+/HER2− advanced breast cancer after endocrine therapy, pembrolizumab plus chemotherapy improved progression-free survival but not overall survival compared with placebo plus chemotherapy.Leggi →
- 08:40MA.40/FINEROnco · Mammella · ER+/HER2-negative metastaticIn patients with ER+/HER2-negative metastatic breast cancer progressing after a CDK4/6 inhibitor plus aromatase inhibitor, ipatasertib plus fulvestrant did not improve overall survival compared with placebo plus fulvestrant.Leggi →
- 09:15UNLOCK 14Onco · Mammella · early triple-negative breast cancerIn patients with untreated cT1N0 triple-negative breast cancer and stromal TILs of at least 5%, short-course preoperative durvalumab rarely achieved a pathological complete response, although it induced frequent immune remodelling of the tumour microenvironment.Leggi →
- 09:25TROPION-Breast02Onco · Mammella · Metastatic triple-negative breast cancerIn patients with metastatic triple-negative breast cancer and asymptomatic, stable brain metastases for whom immunotherapy was not an option, first-line datopotamab deruxtecan was reported to show extracranial efficacy benefit, with preliminary intracranial responses, compared with investigator's choice of chemotherapy.Leggi →
- 09:35Anbenitamab + HB1801 vs THP in HER2+ ABCOnco · Mammella · HER2-positive advancedIn previously untreated HER2-positive advanced breast cancer, anbenitamab plus albumin-bound docetaxel improved progression-free survival by blinded independent review compared with THP.Leggi →
Rapid oral 1: NSCLC, metastatic
08:30–10:00 (Europe/Madrid) · Almeria Auditorium - Hall 9- 08:30PACE-LUNGOnco · Polmone · NSCLC, EGFR-mutantIn patients with EGFR-mutant advanced NSCLC and persistent ctDNA EGFRm after 3 weeks of first-line osimertinib, adding chemotherapy to osimertinib was feasible and was followed by a median progression-free survival of 16.3 months from start of chemotherapy.Leggi →
- 09:00DESTINY-Lung04Onco · Polmone · HER2-mutant metastatic NSCLCIn patients with untreated advanced HER2-mutant NSCLC, trastuzumab deruxtecan delayed deterioration in patient-reported cough compared with pembrolizumab plus chemotherapy.Leggi →
Rapid oral 2: Gynaecological cancers
08:30–10:00 (Europe/Madrid) · Burgos Auditorium - Hall 3- 08:30ZWI-ZW191-101Onco · Gin · ovarianIn heavily pretreated patients with platinum-resistant ovarian cancer, the folate receptor α-targeting antibody-drug conjugate ZW191 produced objective responses in 58% of response-evaluable patients without clear cell carcinoma at both doses tested.Leggi →
- 08:52BEHOLD-1Onco · Gin · ovarianIn patients with platinum-resistant ovarian cancer, mocertatug rezetecan at the highest dose level achieved a confirmed objective response rate of 62% with a median progression-free survival of 11.1 months.Leggi →
Rapid oral: Investigational immunotherapy
08:30–10:00 (Europe/Madrid) · Cadiz Auditorium - NCC- 08:35iNATUREOnco · Other · Tumour-agnostic immunotherapyIn patients with metastatic solid tumours progressing after at least one line of treatment, a personalised neoantigen peptide vaccine plus critical-lesion radiotherapy improved progression-free survival compared with placebo plus critical-lesion radiotherapy.Leggi →
Proffered paper 2: Gastrointestinal tumours, upper digestive
10:15–11:45 (Europe/Madrid) · Alicante Auditorium - Hall 6- 10:25ACTICCA-1Onco · GI · biliary tract cancerIn patients with resected biliary tract cancer, adjuvant gemcitabine and cisplatin did not significantly improve disease-free survival by log rank test compared with capecitabine, although restricted mean survival time favoured the combination.Leggi →
- 11:00EMERALD-3Onco · GI · hepatocellular carcinomaIn people with embolisation-eligible hepatocellular carcinoma across baseline liver function grades, tremelimumab plus durvalumab with or without lenvatinib added to TACE numerically improved post-progression survival and time to next treatment compared with TACE alone while liver function remained stable over treatment.Leggi →
Proffered paper: Genitourinary tumours, prostate, penile and testis
10:15–11:45 (Europe/Madrid) · Barcelona Auditorium - Hall 9- 11:00PROTEUS Substudy vs RP aloneOnco · UG · prostateIn patients with high-risk localised or locally advanced prostate cancer, perioperative apalutamide plus ADT with radical prostatectomy and pelvic lymph node dissection improved event-free survival compared with radical prostatectomy and pelvic lymph node dissection alone.Leggi →
Rapid oral 1: Breast cancer, advanced stage
10:15–11:45 (Europe/Madrid) · Almeria Auditorium - Hall 9- 10:15VIKTORIA-1Onco · Mammella · HR+/HER2- advanced, PIK3CA mutantIn patients with HR+/HER2- PIK3CA-mutant advanced breast cancer, gedatolisib plus palbociclib and fulvestrant improved median progression-free survival compared with alpelisib plus fulvestrant.Leggi →
- 10:37PREDICT-HEROnco · Mammella · HER2-PET imaging biomarkerIn patients with advanced breast cancer starting trastuzumab deruxtecan, a negative HER2-PET scan predicted no objective response with a negative predictive value of 88.2%, meeting the prespecified threshold.Leggi →
Proffered paper: AI and digital health
14:45–16:15 (Europe/Madrid) · Bilbao Auditorium - Hall 3- 14:45BEAGLE-MDTOnco · GI · colorectalIn 15 synthetic colorectal cancer cases reviewed by five expert clinicians, the multi-agent AI platform BEAGLE®-MDT received high clinician ratings for case summarisation, management recommendations and trial matching.Leggi →
- 14:55ALLIANCEOnco · Other · AI and digital healthIn adults with breast or colorectal cancer starting chemotherapy, clinician access to ChatGPT Plus for side effect management did not improve EORTC QLQ-C30 global health status compared with care without LLM access.Leggi →
- 15:39Digital MammaPrint AI assayOnco · Mammella · early breast cancer, prognostic biomarkerIn patients with early-stage breast cancer, an AI-based digital 70-gene assay from routine H&E slides identified a low-risk group with better 10-year breast cancer specific survival.Leggi →
Proffered paper: Gynaecological cancers
14:45–16:15 (Europe/Madrid) · Barcelona Auditorium - Hall 9- 14:55KEYNOTE-B21Onco · Gin · Endometrial cancerIn participants with resected, high-risk dMMR endometrial cancer, adjuvant pembrolizumab plus chemotherapy favoured disease-free survival compared with placebo plus chemotherapy, while ctDNA status had only modest predictive value for disease-specific-free survival.Leggi →
- 15:05DUO-EOnco · Gin · endometrialIn patients with first-line advanced or recurrent endometrial cancer, carboplatin/paclitaxel plus durvalumab followed by durvalumab with or without olaparib showed a favourable but not statistically significant trend in overall survival at an interim analysis compared with carboplatin/paclitaxel alone.Leggi →
- 15:37BEATccOnco · Gin · cervical cancerIn patients with metastatic, persistent or recurrent cervical cancer, adding atezolizumab to first-line chemotherapy plus bevacizumab improved overall survival at the final analysis compared with chemotherapy plus bevacizumab alone.Leggi →
Proffered paper: Sarcoma
14:45–16:15 (Europe/Madrid) · Malaga Auditorium - Hall 3- 14:45TANGENTOnco · Other · sarcomaIn patients with tenosynovial giant cell tumours, short-course emactuzumab improved overall response rate by RECIST v1.1 at 6 months compared with placebo.Leggi →
Rapid oral: Gastrointestinal tumours, lower digestive
14:45–16:15 (Europe/Madrid) · Alicante Auditorium - Hall 6- 15:37PRABITASOnco · GI · colorectalIn patients with refractory metastatic colorectal cancer, biweekly trifluridine/tipiracil plus bevacizumab was non-inferior for overall survival compared with the conventional 28-day schedule, with less neutropenia.Leggi →
- 15:42CheckMate 8HWOnco · GI · colorectalIn patients with MSI-H/dMMR metastatic colorectal cancer, nivolumab plus ipilimumab significantly improved overall survival compared with nivolumab across all treatment lines and chemotherapy in first line.Leggi →
Presidential Symposium I
16:30–18:15 (Europe/Madrid) · Alicante Auditorium - Hall 6- 16:30INTerpath-001Onco · Melanoma · adjuvantIn patients with resected stage IIB-IV melanoma, intismeran plus pembrolizumab improved recurrence-free survival compared with placebo plus pembrolizumab.Leggi →
- 16:54VOLGAOnco · UG · Bladder cancerIn patients with muscle-invasive bladder cancer who were ineligible for or refused cisplatin, perioperative durvalumab plus neoadjuvant enfortumab vedotin improved event-free and overall survival compared with radical cystectomy followed by observation or locally approved adjuvant treatment.Leggi →
- 17:18DeLLphi-305Onco · Polmone · small cell lung cancerIn patients with extensive-stage small cell lung cancer without progression after first-line durvalumab, platinum and etoposide, tarlatamab plus durvalumab maintenance improved overall survival compared with durvalumab alone.Leggi →
- 17:42DASL-HiCaPOnco · UG · prostateIn patients with very high-risk localised or biochemically persistent/recurrent prostate cancer receiving ADT and radiation therapy, adding darolutamide improved metastasis-free survival on conventional imaging compared with placebo.Leggi →
dom 25 ott
Proffered paper 2: Genitourinary tumours, renal and urothelial
08:30–10:00 (Europe/Madrid) · Almeria Auditorium - Hall 9- 08:50PE-PEOnco · UG · renal cell carcinomaIn patients with oligometastatic renal cell carcinoma eligible for metastasis-directed therapy, perioperative pembrolizumab plus metastasis-directed therapy improved relapse-free survival compared with metastasis-directed therapy alone.Leggi →
Proffered paper: Head and neck cancer
08:30–10:00 (Europe/Madrid) · Madrid Auditorium - Hall 4- 08:30HexAgon-HNOnco · ORL · Recurrent/metastatic HNSCC, first lineIn patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma and PD-L1 CPS ≥20, ordastobart plus pembrolizumab increased the confirmed objective response rate compared with pembrolizumab alone.Leggi →
- 08:40TAISHAN-301Onco · ORL · nasopharyngeal carcinomaIn heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, tambotatug pelitecan improved confirmed objective response rate compared with physician's choice chemotherapy.Leggi →
- 09:08PCm vs TPF neoadjuvant oral cancerOnco · ORL · oral cavity cancerIn patients with technically unresectable oral cancers, neoadjuvant weekly paclitaxel and carboplatin with triple oral metronomic chemotherapy was non-inferior for overall survival, with less toxicity, compared with TPF.Leggi →
- 09:18QoLATIOnco · ORL · Oropharyngeal cancerIn patients with early-stage oropharyngeal squamous cell carcinoma, TORS-based treatment improved swallowing-related quality of life at 12 months compared with (chemo)radiotherapy, although the difference did not reach the prespecified threshold for clinical relevance.Leggi →
Rapid oral 2: NSCLC, metastatic
08:30–10:00 (Europe/Madrid) · Barcelona Auditorium - Hall 9- 08:30ROSETTA Lung-107Onco · Polmone · NSCLC, metastatic, after chemoimmunotherapyIn patients with metastatic NSCLC after chemoimmunotherapy, pumitamig plus docetaxel achieved a confirmed objective response rate of 36.7% with a manageable safety profile.Leggi →
Rapid oral: Developmental therapeutic
08:30–10:00 (Europe/Madrid) · Cordoba Auditorium - Hall 4- 08:35GFH276Onco · Other · RAS-mutated solid tumoursIn patients with previously treated RAS-mutated advanced solid tumours who received 40-160 mg in dose escalation, GFH276 monotherapy produced an objective response rate of 36% and a disease control rate of 94%, with no dose-limiting toxicities.Leggi →
- 09:27MRG007Onco · GI · colorectalIn patients with pretreated advanced colorectal cancer, the CDH17-directed exatecan ADC MRG007 produced an objective response rate of 44.8% at the preliminary recommended phase 2 dose, with a manageable safety profile.Leggi →
Proffered paper 1: NSCLC, metastatic
10:15–11:45 (Europe/Madrid) · Alicante Auditorium - Hall 6- 10:53OptiTROP-Lung06Onco · Polmone · NSCLCIn patients with previously untreated PD-L1-negative advanced non-squamous NSCLC, sacituzumab tirumotecan plus pembrolizumab improved progression-free survival compared with chemotherapy plus pembrolizumab.Leggi →
- 11:03OptiTROP-Lung04Onco · Polmone · NSCLC, EGFR-mutatedIn patients with advanced EGFR-mutated NSCLC after progression on EGFR-TKI therapy, sacituzumab tirumotecan improved overall survival at the final analysis compared with pemetrexed plus platinum chemotherapy.Leggi →
- 11:13SigVie-002Onco · Polmone · NSCLC, previously treated nonsquamousIn patients with previously treated nonsquamous non-small cell lung cancer, sigvotatug vedotin did not improve overall survival compared with docetaxel.Leggi →
Proffered paper: Gastrointestinal tumours, lower digestive
10:15–11:45 (Europe/Madrid) · Almeria Auditorium - Hall 9- 10:15IROCASOnco · GI · colorectalIn patients with high-risk stage III colon cancer, adjuvant mFOLFIRINOX did not improve 3-year disease-free survival compared with mFOLFOX6.Leggi →
- 10:25EMT2Onco · GI · colorectalIn patients undergoing resection of colorectal cancer liver metastases, eicosapentaenoic acid did not improve progression-free survival compared with placebo, although overall survival, a secondary endpoint, was nominally improved.Leggi →
- 11:00AZUR-1Onco · GI · rectal cancerIn patients with dMMR/MSI-H locally advanced rectal cancer, dostarlimab monotherapy achieved a clinical complete response sustained for 12 months by investigator assessment in 68% of evaluable patients without chemotherapy, radiation or surgery.Leggi →
Proffered paper: Policy
10:15–11:45 (Europe/Madrid) · Seville Auditorium - NCC- 11:13OPTIMAOnco · Mammella · early breast cancer, health economicsIn patients aged 40 or older with ER-positive HER2-negative early breast cancer and 0-9 involved nodes, chemotherapy directed by the 50-gene Prosigna assay improved quality-adjusted life-years and net health benefit over 2 years at a similar cost compared with chemo-endocrine therapy for all.Leggi →
Rapid oral: Melanoma and other skin tumours
10:15–11:45 (Europe/Madrid) · Granada Auditorium - Hall 4- 10:42C-POSTOnco · Melanoma · Cutaneous squamous cell carcinomaIn patients with high-risk cutaneous squamous cell carcinoma after surgery and postoperative radiotherapy, adjuvant cemiplimab improved disease-free survival compared with placebo.Leggi →
- 10:47ADMEC-OOnco · Melanoma · Merkel cell carcinomaIn patients with completely resected stage I-IV Merkel cell carcinoma, one year of adjuvant nivolumab did not significantly improve disease-free or overall survival compared with observation.Leggi →
- 11:09Formula-10Onco · Melanoma · extramammary Paget's diseaseIn patients with HER2-high locally advanced or metastatic extramammary Paget's disease, disitamab vedotin achieved a high confirmed objective response rate with manageable toxicity.Leggi →
Proffered paper 1: Basic science and translational research
14:45–16:15 (Europe/Madrid) · Cordoba Auditorium - Hall 4- 14:45TRACERxOnco · Polmone · ctDNA and minimal residual diseaseIn patients with early-stage non-small cell lung cancer, landmark ctDNA detection by error-corrected plasma whole-genome sequencing was associated with shorter recurrence-free and overall survival.Leggi →
Proffered paper: Prevention, early detection and intervention
14:45–16:25 (Europe/Madrid) · Granada Auditorium - Hall 4- 14:45Fragmentomic-proteomic lung cancer testOnco · Polmone · early detectionIn individuals with or without lung cancer, an integrated cfDNA fragmentomic-proteomic machine learning classifier detected lung cancer with an AUC of 0.91, validated in an independent prospective cohort.Leggi →
Rapid oral: Head and neck cancer
14:45–16:15 (Europe/Madrid) · Madrid Auditorium - Hall 4- 14:45RADIANOnco · ORL · Locally advanced HNSCCIn patients with locally advanced head and neck squamous cell carcinoma fit for cisplatin chemoradiotherapy, niraparib and dostarlimab added to chemoradiotherapy improved 1-year disease-free survival against historical data, but in cisplatin-unfit patients given radiotherapy alone it increased toxicity without a disease-free survival benefit.Leggi →
- 15:39OPTIMALOnco · ORL · Oral cavity, perioperative immunotherapyIn patients with resectable locally advanced oral squamous cell carcinoma, neoadjuvant tislelizumab with chemotherapy followed by response-adapted, radiotherapy-free adjuvant tislelizumab has not yet been shown to improve 2-year event-free survival compared with surgery followed by standard postoperative radiotherapy or chemoradiotherapy.Leggi →
Presidential Symposium II
16:30–18:15 (Europe/Madrid) · Alicante Auditorium - Hall 6- 16:30Krascendo 1Onco · Polmone · NSCLC, KRAS G12C, previously treatedIn patients with previously treated advanced or metastatic KRAS G12C-mutated NSCLC, divarasib improved progression-free and overall survival compared with investigator's choice of sotorasib or adagrasib.Leggi →
- 16:54SAFFRONOnco · Polmone · EGFR-mutated NSCLCIn patients with EGFR-mutated, MET-overexpressed and/or -amplified advanced NSCLC after osimertinib, osimertinib plus savolitinib improved progression-free and overall survival compared with platinum-pemetrexed.Leggi →
- 17:18CLARITY-Gastric 01Onco · GI · gastroesophagealIn previously treated advanced CLDN18.2-positive gastroesophageal carcinoma, sonesitatug vedotin improved overall survival compared with investigator's choice of chemotherapy-based therapy.Leggi →
- 17:42HARMONi-GI1Onco · GI · biliary tract cancerIn patients with advanced biliary tract cancer, ivonescimab plus chemotherapy improved overall survival compared with durvalumab plus chemotherapy.Leggi →
Rapid oral: Supportive and palliative care
16:30–18:00 (Europe/Madrid) · Murcia Auditorium - Hall 3- 16:55FORXOnco · Other · Supportive care: diet and immunotherapy toxicityIn patients with solid tumours starting immune checkpoint inhibitors, a 30-plant-per-week diet over 12 weeks was feasible and was followed by at least one irAE in 51.9% and grade ≥3 toxicity in 3.7% in a single-arm study without a comparator.Leggi →
lun 26 ott
Proffered paper 2: NSCLC, metastatic
08:30–10:00 (Europe/Madrid) · Alicante Auditorium - Hall 6- 08:30SANOVOOnco · Polmone · NSCLC, EGFR-mutant with MET overexpressionIn treatment-naive patients with EGFR-mutant, MET-overexpressing advanced NSCLC, savolitinib plus osimertinib improved investigator-assessed progression-free survival compared with placebo plus osimertinib.Leggi →
- 09:14PANKU-Lung01Onco · Polmone · EGFR-mutant NSCLCIn patients with EGFR-mutant non-squamous NSCLC after progression on a third-generation EGFR TKI, iza-bren improved progression-free survival compared with platinum-based chemotherapy.Leggi →
- 09:24HERON-Lung01Onco · Polmone · NSCLC, EGFR-mutatedIn patients with EGFR-mutated advanced nonsquamous NSCLC progressing after EGFR-TKI, ruzaltatug rezetecan improved progression-free survival compared with platinum-based chemotherapy.Leggi →
Proffered paper: Supportive and palliative care
08:30–10:00 (Europe/Madrid) · Burgos Auditorium - Hall 3- 08:30Sleepio After CancerOnco · Other · supportive care: insomniaIn women with cancer and insomnia, digital cognitive behavioural therapy for insomnia improved the Sleep Condition Indicator score at week 24 compared with sleep hygiene education.Leggi →
- 08:40HOPE ESMO 2026Onco · Mammella · supportive careIn patients with stage I-III HR+ early breast cancer reporting endocrine therapy symptoms, a personalised digital supportive-care pathway added to standard of care did not significantly improve endocrine therapy symptom burden at 3 months compared with standard of care alone.Leggi →
Proffered paper: NETs and endocrine tumours
10:15–11:45 (Europe/Madrid) · Murcia Auditorium - Hall 3- 10:15LBL-024Onco · Other · neuroendocrine carcinomaIn patients with advanced extra-pulmonary neuroendocrine carcinoma after at least two prior lines of therapy, opamtistomig monotherapy achieved an independently assessed objective response rate of 26.0%, meeting the prespecified threshold.Leggi →
Rapid oral 2: Basic science and translational research
10:15–11:45 (Europe/Madrid) · Cordoba Auditorium - Hall 4- 11:09S1823/GCC.1Onco · UG · Germ cell tumour biomarkerIn patients with early-stage germ cell tumours on active surveillance, plasma miR371 detected relapse with a sensitivity of 0.54 at relapse and a specificity of 0.90.Leggi →
- 11:14CURESPONSEOnco · Other · Functional precision oncology, pan-tumourIn patients with advanced or metastatic malignancies undergoing biopsy before systemic therapy, ex vivo organ culture testing of the planned treatment predicted objective radiological response at 2 months with 71% sensitivity, 82% specificity and a 91.7% negative predictive value.Leggi →
Rapid oral 2: Breast cancer, advanced stage
10:15–11:45 (Europe/Madrid) · Alicante Auditorium - Hall 6- 11:00DESTINY-Breast09Onco · Mammella · HER2-positive metastaticIn patients with HER2-positive advanced breast cancer and baseline brain metastases, trastuzumab deruxtecan plus pertuzumab prolonged CNS progression-free survival compared with taxane, trastuzumab and pertuzumab.Leggi →
Rapid oral: Non-metastatic NSCLC and other thoracic malignancies
10:15–11:45 (Europe/Madrid) · Burgos Auditorium - Hall 3- 10:35MDT-BRIDGEOnco · Polmone · Perioperative NSCLCIn patients with resectable or borderline resectable stage IIB-IIIB NSCLC receiving neoadjuvant durvalumab plus chemotherapy, ctDNA clearance before surgery or chemoradiotherapy was associated with higher pathological complete response rates and better 12-month event-free and progression-free survival.Leggi →
- 10:40CTONG 1804Onco · Polmone · locally advanced NSCLCIn patients with potentially resectable or unresectable stage III NSCLC, induction chemoimmunotherapy enabled surgical conversion in 48.8% of patients, with a 12-month event-free survival of 84.6% after surgery.Leggi →
Proffered paper: Non-metastatic NSCLC and other thoracic malignancies
14:45–16:15 (Europe/Madrid) · Alicante Auditorium - Hall 6- 15:23NeotorchOnco · Polmone · Perioperative NSCLCIn patients with resectable stage II or III non-small cell lung cancer, perioperative toripalimab plus chemotherapy improved event-free survival, major pathological response and overall survival compared with placebo plus chemotherapy.Leggi →
Rapid oral 2: Gastrointestinal tumour, upper digestive
14:45–16:15 (Europe/Madrid) · Barcelona Auditorium - Hall 9- 14:45HRS-4642Onco · GI · pancreaticIn patients with resectable or borderline resectable KRAS G12D-mutant pancreatic cancer, perioperative HRS-4642 plus gemcitabine and nab-paclitaxel, with or without adebrelimab, produced objective responses in 63% and 87% of patients with manageable toxicity.Leggi →
- 15:29OPTIMUMOnco · GI · biliary tract cancerIn patients with DDR gene-mutated advanced biliary tract cancer without progression on first-line platinum-based therapy, maintenance olaparib with or without durvalumab achieved a 6-month progression-free survival rate of 62.3% in the full analysis set, above the historical 48.0% used to power the trial.Leggi →
Presidential Symposium III
16:30–18:15 (Europe/Madrid) · Alicante Auditorium - Hall 6- 16:30ARTEMIS-011Onco · Other · sarcomaIn Chinese patients with heavily pretreated relapsed or refractory osteosarcoma, risvutatug rezetecan improved progression-free survival assessed by blinded independent central review compared with gemcitabine and docetaxel.Leggi →
- 16:54MOIOOnco · Other · Immunotherapy de-escalationIn patients with advanced or metastatic solid tumours responding to immune checkpoint inhibitors, reduced dose-intensity immunotherapy was not non-inferior for progression-free survival compared with standard dose-intensity immunotherapy.Leggi →
- 17:18TroFuse-005Onco · Gin · endometrialIn patients with advanced or recurrent endometrial cancer previously treated with platinum and anti-PD-1/PD-L1 therapy, sacituzumab tirumotecan improved progression-free and overall survival compared with physician's choice of doxorubicin or paclitaxel.Leggi →
- 17:42KEYNOTE-C93Onco · Gin · endometrialIn patients with dMMR advanced or recurrent endometrial carcinoma, first-line pembrolizumab improved progression-free survival compared with carboplatin plus paclitaxel.Leggi →